Smart insulin system aims to protect moms and babies in diabetes pregnancy
NCT ID NCT07240012
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tests whether an automated insulin delivery system (CamAPS FX) can help women with type 1 diabetes maintain better blood sugar control before and during pregnancy, compared to their usual insulin routine. The trial will enroll 305 women aged 18-45 who are either planning pregnancy or in early pregnancy. The goal is to improve time in target blood sugar range and reduce risks like abnormal fetal growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY COMPLICATIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Pregnant Women with Diabetes, Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
-
Department of Gynecology and Obstetrics, Aalborg University Hospital
RECRUITINGAalborg, Aalborg, 9000, Denmark
-
Department of Gynecology and Obstetrics, Aarhus University Hospital
NOT_YET_RECRUITINGAarhus, Aarhus N, 8200, Denmark
-
Department of Gynecology and Obstetrics, Odense University Hospital
RECRUITINGOdense, Odense C, 5000, Denmark
-
Steno Diabetes Center Aarhus
NOT_YET_RECRUITINGAarhus, Aarhus N, 8200, Denmark
-
Steno Diabetes Center Copenhagen
NOT_YET_RECRUITINGCopenhagen, Herlev, 2730, Denmark
-
Steno Diabetes Center Nordjylland
RECRUITINGAalborg, Gistrup, 9260, Denmark
-
Steno Diabetes Center Odense, Odense University Hospital
RECRUITINGOdense, Odense C, 5000, Denmark
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Automated closed-loop insulin delivery system (CamAPS FX algorithm with continuous glucose monitor)
What this could lead to
If successful, this could offer a more effective way to manage blood sugar during pregnancy, potentially reducing complications for both mother and baby.
What could go wrong
This is a relatively early-stage trial with 305 participants, and results may not apply to all. The device may not work as well in real-world settings or could have technical issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.